Peptides DB
Research-centric peptide and protocol reference hub

Pramlintide record · updated 6h ago

Metabolic & appetiteNeuro & moodGrade B · human evidenceResearch use only
All 9 studiesJump to the evidenceCompare
What is Pramlintide used for?

Research peptide discovered via AI researcher. peptide-based therapeutic

Primarily researched for · Metabolic & appetite

Development stage

where Pramlintide sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 60 registered trials. It describes the research record, not a recommendation.

Identity
NamePramlintide
Chain length—
Molecular weight3,949 Da
FormulaC171H267N51O53S2
Structure typeNot established
ClassMetabolic
Research levelLimited Research
Discovered byThe Librarian · 2026

Mass and formula from PubChem CID 70691388. No verified residue count for this compound.

Pharmacology
Mechanism—
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence—
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 9, 2026. How this works →
Research stats
Total studies9
Human / animal / cellular2 / 3 / 0
Highest trial phasePreclinical
Years covered2022–2026
Latest study13d ago
Publication history
20222026
Research funding
128 NIH projects · $23.5M awarded · through FY2025
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports109
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

9 rowsOpen in the library →
StudyTypeYearSummary depth
Real-World EHR Signals from a Cohort of Blinded Incretin Trial Participants Motivate Novel Indication Opportunities
Finding-7.7% weight loss in masked CagriSema/placebo cohort vs -10.2% in tirzepatide, P=0.27
Human2026Full text read0.80
Oral delivery of the amylin receptor agonist pramlintide
FindingOral delivery of microparticles showed a release duration of 120 min compared to 30 min for pramlintide in solution.
Animal2023Full text read0.70
Sexually dimorphic effects of Amylin 1 receptor activation in trigeminovascular neurons
FindingNot reported in abstract.
Animal2024Full text read0.70
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
FindingNot reported in abstract.
review2026Partial text0.40
Immune pathways and prenatal/perinatal environmental exposures contribute to epigenetic gestational age prediction and acceleration.
FindingR² = 0.88 for multi-CpG site model predictive accuracy.
Human2026Full text read0.80
The cyclin dependent kinase (CDK)7 inhibitor BS-181 inhibits pathogenic Cryptococcus species, causing G<sub>2</sub>/M arrest and a splicing defect.
Finding2-4-fold reduction in the amphotericin B MIC with BS-181.
Animal2026Full text read0.70
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
TakeawayNot reported in abstract.
—2022Title only0.00
The story of amylin: from physiology to therapy.
TakeawayNot reported in abstract.
—2026Title only0.10
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
TakeawayNot reported in abstract.
—2026Title only0.10

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Pramlintide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Pramlintide is discussed should be drawn from it.